Kanoh Y, Jimbo S, Shibuya M, Matsuyama N, Mashiko T, Tanaka T, Egawa S, Ohtani H
Department of Clinical Pathology, Kitasato University School of Medicine, Sagamihara.
Rinsho Byori. 1998 Sep;46(9):923-9.
Prostate-specific antigen (PSA) is present in blood in free form as well as in complex form with various protease inhibitors such as alpha 2 macroglobulin (alpha 2M) and alpha 1 antichymotrypsin (alpha 1 ACT). We had found that alpha 2M is deficient (below approximately 40 mg/dl) in some patients with prostatic carcinoma. Therefore, we investigated the levels of free and complex form of PSA in patients with prostatic disease and obtained the following results. The HPLC study showed that total (free plus complex) PSA level was much higher in the alpha 2M deficient patients with prostatic carcinoma stage D (n = 7, range 1,530-14,746 ng/ml, median value 6,800 ng/ml) than in the non-deficient patients with stage D (n = 16, range 121.6-4,210 ng/ml, median value 851 ng/ml). In the deficient patients, the complex of PSA with alpha 1 ACT increased extraordinarily while free PSA increased to only some extent. In the more severe cases of prostatic carcinoma, the ratio (complex/total PSA) was higher while the ratio (free/total PSA) was lower. The SDS-PAGE Western blotting showed that complex PSA increased extraordinarily and free PSA increased in sera of the deficient patients which was consistent with the HPLC results. Many bands appeared on the blotting at the positions smaller than alpha 2M molecule, which indicated that many fragments of alpha 2M were present in their sera. These bands were more intense than the bands with sera of controls or benign prostatic hypertrophy. The alpha 2M deficiency may be due to the rapid disappearance of the complex with PSA or any other prostate-originated proteases. The complex may undergo accelerated degradation or catabolism of alpha 2M.
前列腺特异性抗原(PSA)以游离形式以及与各种蛋白酶抑制剂如α2巨球蛋白(α2M)和α1抗糜蛋白酶(α1ACT)结合的形式存在于血液中。我们发现,一些前列腺癌患者的α2M缺乏(低于约40mg/dl)。因此,我们研究了前列腺疾病患者中游离和结合形式的PSA水平,得到以下结果。高效液相色谱研究表明,α2M缺乏的D期前列腺癌患者(n = 7,范围1530 - 14746ng/ml,中位数6800ng/ml)的总(游离加结合)PSA水平比非缺乏的D期患者(n = 16,范围121.6 - 4210ng/ml,中位数851ng/ml)高得多。在缺乏的患者中,PSA与α1ACT的复合物异常增加,而游离PSA仅略有增加。在前列腺癌更严重的病例中,(复合物/总PSA)比值更高,而(游离/总PSA)比值更低。十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳(SDS - PAGE)免疫印迹显示,缺乏患者血清中的结合PSA异常增加,游离PSA增加,这与高效液相色谱结果一致。在印迹上,小于α2M分子大小的位置出现了许多条带,这表明他们的血清中存在许多α2M片段。这些条带比对照血清或良性前列腺增生血清的条带更明显。α2M缺乏可能是由于与PSA或任何其他前列腺来源的蛋白酶形成的复合物快速消失所致。该复合物可能会加速α2M的降解或分解代谢。